News and Trends 10 Mar 2025 23andMe: the collapse of a genomics giant 23andMe was once worth $6 billion and is now a penny stock. Layoffs, data breaches, and mass resignations plagued the genomics giant. How did it all unfold? March 10, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2024 Second biotech IPO boom of the year: what does it mean for the industry? Discover why biotech is experiencing a second IPO boom in 2024 and what it means for the broader industry. October 10, 2024 - 9 minutesmins - By Monica Karpinski Share WhatsApp Twitter Linkedin Email
In Depth 26 Jun 2024 Biotech megadeals: Exploring the surge in $100M+ deals Biotech and healtcare contributed to more than one out of three megadeals in 2024, find out the reasons behind it. June 26, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 19 Apr 2024The biotech investment landscape in 2024 Dive into 2024’s biotech investment strategies with RTW Investments on our podcast. Discover trends shaping the landscape ahead.” April 19, 2024 Share WhatsApp Twitter Linkedin Email
In Depth 8 Apr 2024 A wave of biotech layoffs: will the trend continue throughout 2024? Thousands of jobs have been at risk over the past year due to mass layoffs by biotech companies across the globe. April 8, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Mar 2024 Will the US biotech funding surge trigger a renaissance in the global biotech industry? After a couple of challenging years in biotech investment, the US leads the march for recovery. Delve into the specifics driving this uptick. March 18, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2024 Is the biotech industry poised for recovery in 2024? The past few years have been challenging for the industry but 2024 might be the year marking the biotech recovery. January 8, 2024 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 11 Sep 2023 Evolving biotech funding trends: VCs lead new series B deals, but early-stage deals require insider support With biotech funding trends always evolving, HSBC Innovation Banking’s inaugural Venture Healthcare Report lays out the trends seen in the first half (1H) of 2023, where valuations underwent a necessary reset, and venture capitalists emerged from their cautious stance, eventually embarking on a fresh wave of investments. However, an overall decline in investment was still […] September 11, 2023 - 5 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jan 2022 Two Gene Therapy Players Launch IPOs on Stormy Stock Market After a drought of more than a year, the European gene therapy sector saw initial public offerings from Genenta Science and Genflow Biosciences. The firms aim to shine as biotech stocks elsewhere perform poorly. Until recently, European gene therapy companies were going through a dry spell in terms of launching initial public offerings (IPO). The […] January 21, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2021 Evotec IPO Hints At Stabilizing Investor Interest In Biotech Stocks German life sciences heavyweight Evotec raised around €376M ($435M) in its US debut on the Nasdaq last week, fueling tentative hopes of renewed investor interest in biotech stocks after a rollercoaster year. The company downsized its initial IPO target of around €500M ($576M) by offering fewer shares than initially planned. This is widely seen as […] November 10, 2021 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2021 Third-Generation DNA Sequencing Shines with Oxford Nanopore’s IPO Oxford Nanopore Technologies, until recently one of very few unicorns in the European biotech industry, had a stellar IPO on the London Stock Exchange late last month. This is ushering in a whole new generation of DNA sequencing, genetics research, and diagnostics. During the first day of the IPO, which bagged the firm over €400M […] October 15, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2021 Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts to use artificial intelligence to fuel drug discovery, with global tech investors often taking the lead. The Oxford, UK-based company Exscientia has one of the most mature artificial intelligence (AI)-focused drug discovery pipelines, alongside companies like BenevolentAI in the UK, […] October 7, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email